UTMD

Business Context and Reporting Period

Company: Utah Medical Products Inc. (UTMD)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: UTMD designs, manufactures, and distributes specialized medical devices for critical care, labor and delivery, neonatal intensive care, and gynecology. The company operates manufacturing facilities in Utah and Ireland, with distribution subsidiaries in the UK, Canada, and Australia. Key products include the Filshie Clip System (female sterilization), INTRAN PLUS (intrauterine pressure monitoring), and various neonatal catheters.

Key Financial Metrics (Year Ended Dec 31, 2024)

Material Changes vs. Prior Period

• Revenue Decline: Consolidated sales decreased 18.6% to $40.9 million. The primary driver was a 45.7% drop in U.S. OEM sales, specifically a $5.9 million reduction from the largest customer, PendoTECH, which is integrating its own manufacturing. OUS distributor sales also declined 28.1%.
• Margin Stability: Despite the revenue drop, gross and operating margins remained relatively stable. Operating income margin held at 33.2% (vs. 33.4% in 2023), aided by the full amortization of a $21 million intangible asset (CSI distribution rights) in 2023, which eliminated $3.7 million in non-cash expenses for 2024.
• Increased Litigation Costs: Legal expenses related to Filshie Clip System product liability lawsuits increased to $2.1 million in 2024 from $1.7 million in 2023.
• Shareholder Returns: The company repurchased 301,961 shares for $20.0 million in 2024 and paid $4.3 million in cash dividends. Total capital returned to shareholders was $24.2 million.

Guidance, Outlook, and Risks

• 2025 Outlook: Management projects a revenue decrease of approximately 5% (about $2 million) in 2025 compared to 2024. This is due to the continued decline in PendoTECH sales (expected to drop another $2.5 million) and potential softness in U.S. Filshie sales. EPS is expected to decline by approximately 10% to a target of $3.60.
• Product Liability Litigation: The company faces ongoing lawsuits regarding the Filshie Clip System (alleged clip migration). As of March 2025, ten cases have been dismissed, and five have been resolved via summary judgment. Three summary judgment motions remain pending. Management believes the chance of avoiding trial is significant and expects litigation expenses to decrease by $200,000 in 2025.
• Strategic Focus: UTMD plans to introduce high-pressure process control transducers directly to biopharmaceutical manufacturers and continue opportunistic share repurchases and dividends.
• Risks: Key risks include the loss of the PendoTECH customer, the outcome of Filshie litigation, foreign currency exchange fluctuations (74% of OUS sales are in foreign currencies), and regulatory burdens.

Investor Verification Checklist

• PendoTECH Exposure: Verify the trajectory of sales to PendoTECH, which dropped from $8.6M (2023) to $2.7M (2024) and is projected to decline further in 2025.
• Filshie Litigation Status: Monitor the resolution of the three pending summary judgment motions and any new filings, as trial costs could materially impact expenses.
• Foreign Currency Impact: Assess the impact of a strengthening USD on OUS revenues, which comprised 43% of total sales in 2024.
• Intangible Asset Amortization: Confirm that the $3.7M non-cash expense from the CSI distribution rights amortization is fully removed from 2024 and 2025 results, providing a clearer view of operating cash flow.
• Cash Deployment: Review the balance between share repurchases ($20M in 2024) and potential accretive acquisitions given the $83M cash balance.